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‘Take home’ message:  High proportion of children with MDR-TB had favourable outcome (90%) with 
early diagnosis and treatment initiation.  
 
 
 
 
 
Multidrug-resistant tuberculosis in children in Northwest Russia: an observational cohort study 
 
Russia has the third highest absolute number of multidrug-resistant (MDR) tuberculosis (TB) cases in the 
world [1], yet little is known about the scale of childhood MDR-TB in the country; available publications 
are limited to small case series in older children [2,3]. Successful treatment outcomes for children with 
MDR-TB vary widely in other settings, ranging from 53% to 97% [4].  
 
The Arkhangelsk Region has one of the highest rates of MDR-TB in Russia [5]. The first paediatric MDR-
TB case was registered in 2001. The Arkhangelsk Regional Tuberculosis Dispensary, a State Healthcare 
tertiary TB centre, coordinates care for all patients with drug-resistant TB in the region and works closely 
with two paediatric sanatoriums. 
 
We conducted a retrospective cohort study of all children (<18 years) diagnosed with MDR-TB in the 
region, from 01/01/2001 to 31/12/2012 with follow-up data to 31/12/2015. Data were extracted from 
patient health records and treatment cards. In the Russian national TB programme, childhood TB is 
disaggregated into younger children (<15 years) and adolescents (15 to <18 years). This cut-off was 
preserved to align with country reporting.    
 
MDR-TB was considered as confirmed or clinically-diagnosed. Confirmed cases were verified by culture 
and drug sensitivity testing and/or molecular testing. Clinically-diagnosed cases were defined according 
to published consensus definitions [6] and TB severity was categorised based on established criteria [7]. 
Children with sputum smear- or culture-positive MDR-TB were treated as in-patients at the Dispensary 
until they were considered non-infectious; most sputum culture-negative cases were treated in the 
paediatric sanatoriums. A few children were managed at home with directly observed therapy (DOT). 
 
Tuberculin skin testing (TST) was performed at baseline and repeated at six weeks if initially negative. 
Toxicity monitoring included full blood count, blood biochemistry, urinalysis, thyroid stimulating 
hormone (TSH) and hearing evaluation. Children ≥4 years treated in the Dispensary underwent pure 
tone audiometry; all children <4 years and children treated in sanatoriums had whispered voice testing 
administered by trained clinicians. Patients treated with ethambutol underwent monthly ophthalmology 
review. Other paediatric specialists (endocrinologists, nephrologists and psychologists) reviewed 
children as required.  
  
Treatment outcomes were classified as per WHO definitions [8]. Comparisons between baseline 
characteristics in the two age groups were made using Fisher’s exact test for categorical variables and 
Wilcoxon’s rank-sum (Mann-Whitney) test for continuous variables, and unadjusted Poisson regression 
was used to compare the number of grade 3-4 events. Statistical analyses were done with Stata version 
14.0. Written informed consent was obtained from children’s families at the time of MDR-TB diagnosis. 
The study received research ethics approval from the Northern State Medical University, Arkhangelsk. 
 
Over the study period, the TB incidence rate in children decreased from 12-15 per 100,000 population in 
2001-2009 to 7-9/100,000 in 2010-2012; the proportion of MDR cases ranged from 4.9 to 42%.  Overall, 
of 366 children diagnosed with TB, 56 (15%) were MDR. Clinical and treatment characteristics were 
available for 52 children. Median age at diagnosis was 10.6 years (interquartile range (IQR): 5.0-15.9). 
Overall, in 48 (92%) children an adult source case with MDR-TB was identified; 33 (63%) children were 
diagnosed following contact screening. Twenty-eight (54%) children were asymptomatic and 41 (79%) 
had TST induration ≥10mm. Twenty-eight (54%) children had pulmonary TB; seven had cavities. All 
children were tested for HIV; none were positive. Seventeen children (33%) had confirmed MDR-TB: 16 
had positive culture, including one child with XDR-TB, and 1 was confirmed by nucleic acid amplification 
test (GenoTypeMTBDRplus) only. Nine (17%) had severe TB at diagnosis (Table).  
 
Most children were treated in hospital or sanatoriums; only three had full treatment at home. Overall 
median treatment duration was 21.7 months (IQR 17.0-24.0). Treatment regimens were constructed 
based on the existing WHO recommendations. Younger children received a shorter duration of 
injectable drugs compared to adolescents (p<0.001) (Table). 
 
Adverse reactions were experienced by 25 (48%) children. Eight children had 10 moderate to severe 
reactions (5 raised transaminases, 5 eosinophilia), with temporary treatment interruption in four (3 
drug-induced hepatitis, 1 severe eosinophilia). One child had treatment discontinuation due to mild 
renal toxicity. Nausea and/or vomiting were observed in 5 of 40 (13%) children treated with 
prothionamide. Twenty children (38%) developed increased liver transaminases. TSH elevation was 
observed in 15 children treated with prothionamide and/or PAS (15/48, 31%); all remained 
asymptomatic and received levothyroxine until MDR-TB treatment completion. Two children on 
cycloserine (2/41, 5%) had emotional liability and irritability. Four children (4/52, 8%) complained of 
persistent knee joint pain; one had elevated uric acid and received allopurinol. One of 26 children tested 
by pure tone audiometry had mild hearing loss. All other children were tested by whispered voice; they 
had no clinically significant hearing loss during follow-up. 
 
All 52 children were followed up for at least 18 months post treatment; none were lost to follow-up. 
Forty-seven (90%) had successful outcomes (16 achieved cure and 31 completed treatment). Three 
children did not complete treatment: one stopped after 3.7 months for drug-related nephrotoxicity and 
two adolescents discontinued at 7.7 and 12.4 months. All three were sputum smear/culture-negative 
and improved despite premature treatment discontinuation. One child relapsed; completed a 14 
months re-treatment regimen without recurrence. One patient, diagnosed aged 13 years with sputum 
smear/culture-positive MDR-TB, resistant to all first-line drugs and ethionamide, died at age 21 years 
from extensive pulmonary TB.  
 
Most children (63%) were identified through contact screening. In contrast to other contexts with high 
rates of TB in children aged less than five years [9], our data show a relatively low proportion of the 
caseload in this age group. This is consistent with another study from Pakistan which demonstrated that 
children aged over five years had similar rates of MDR-TB to younger children [10]. Over half of the 
children were asymptomatic with only radiological manifestations at diagnosis, and two-thirds had 
clinically-diagnosed MDR-TB. The findings suggest that contact tracing and subsequent close follow-up 
allowed early diagnosis of MDR-TB; the decision to treat children with symptoms suggestive of TB and 
contact history without bacteriological confirmation allowed for timely treatment initiation. 
 
Successful outcomes were achieved in 90% of children. Younger children had predominantly non-severe 
TB and a shorter duration of injectable treatment. This is consistent with other paediatric studies [4, 11, 
12]. Our study showed high rates of successful treatment in adolescents in contrast to other recent 
studies reporting poor outcomes in this age group [13,14]. Daily DOT administered by medical personnel 
may well have contributed to this. Although nearly half of the children experienced adverse reactions, 
most were actively managed, allowing continuation of the prescribed regimen in most children.  
 
This study has limitations of retrospective design and suboptimal hearing assessment in most children, 
therefore, the hearing loss was likely to be underestimated.  
 
The treatment of MDR-TB in children is complex, challenging, of long duration, and is associated with 
high rates of adverse reactions. Improved regimens are urgently needed and the new drugs, bedaquiline 
and delamanid, could play a more prominent role in paediatric MDR-TB treatment [15,16]. In spite of 
this, however treatment success was achieved in most children with a proactive approach to contact 
tracing, early treatment based on clinical diagnosis, structured approach to the construction of drug 
regimens based on the international recommendations, and the active management of adverse 
reactions.  
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Table 1  Multidrug-resistant tuberculosis in children in the Arkhangelsk region: baseline characteristics 
at diagnosis, treatment duration and outcome. 
 Children        
(<15 years at 
diagnosis) 
(n=36) 
Adolescents (15 
to <18 years at 
diagnosis) 
(n=16) 
Overall 
(n=52) 
P-value 
 median (IQR) or n (%) or number of events (number of 
patients)  
 
Age  at diagnosis of  MDR-TB disease   7.0 (4.1, 10.9) 16.6 (15.9, 17.2) 10.6 (5.0, 15.9) n/a 
Male gender 13 (36%)  8 (50%)  21 (40%) 0.3753 
Methods of case finding    0.2203 
    Contact tracing 25 (69%)  8 (50%)  33 (63%)  
    Annual routine TST screening¤ 6 (17%)  3 (19%)  9 (17%)  
    Fluorography screening¤ - 3 (19%)  3 (4%)  
    Presented with symptoms  5 (14%)  2 (13%)  7 (13%)  
Identified source case with MDR-TB  32 (89%) 16 (100%) 48 (92%) 0.2988 
TST    0.2377 
    <5mm 5 (14%)  0  5 (10%)  
    5-<10mm 3 (8%)  3 (18%)  6 (12%)  
    ≥10mm 28 (78%) 13 (81%) 41 (79%)  
Type of  MDR-TB    0.0001* 
    Pulmonary only 5 (14%)  12 (75%)  17 (33%)  
    Extrapulmonary only 21 (58%)  3 (19%)  24 (46%)  
    Pulmonary and extrapulmonary 10 (28%) 1 (6%) 11 (21%)  
Presenting symptoms    0.0384 
    TB-related symptoms§ 13 (36%)  11 (69%)  24 (46%)  
    Asymptomatic 23 (64%)  5 (31%)  28 (54%)  
Microbiological confirmation     0.3400 
    Positive culture or NAAT 10 (28%)  7 (44%)  17 (33%)   
Severity of disease    0.1132 
    Severe 4 (11%)   5 (31%)  9 (17%)  
    Non-severe 32 (89%)  11(69%)  43 (83%)  
Treatment duration     
    Duration of hospital admission in  
    months  (n=5,10,15) 
3.0 (2.7, 6.3) 4.5 (3.0, 5.5) 4.1 (3.0, 5.7) 0.8065 
    Duration of sanatorium treatment in  
    months  (n=31,5,36) 
18.1 (14.9, 22.6) 8.2 (6.7, 12.3) 17.6 (12.6, 22.1) 0.0163 
    Duration of treatment in months  20.8 (16.4, 22.8) 22.8 (19.2, 26.4) 21.7 (17.0, 24.0)  0.1268 
    Duration of treatment with injectables   
    in months  (n=33,16,49)ǂ 
 4.3 (3.0, 6.1) 7.6 (6.2, 9.3) 5.9 (3.3, 7.4) 0.0002 
Grade 3-4 adverse reactions¥ 6 (5) 4 (3) 10 (8) 0.5299# 
    Elevated ALT and/or AST 4 1 5  
    Eosinophilia (asymptomatic) 2 3 5  
Outcome    0.6374˄ 
    Favourable outcome 33 (92%)  14 (88%)  47 (90%)  
Cure 9  7  16   
Treatment completed 24  7 31   
    Unfavourable outcome 3 (8%)  2 (13%)  5 (10%)  
Relapse or recurrence of MDR-TB 1 0 1  
Treatment incomplete  1 2 3  
Treatment failed, died 1 0 1  
ALT: alanine aminotransferase; AST: aspartate aminotransferase; LN: lymph nodes; NAAT: nucleic acid 
amplification tests; n/a: not applicable; TST: tuberculin skin test. ¤ Part of routine TB screening in Russia: annual 
TST in all children and two yearly fluorography in children aged 15-18 years. § Cough, fever, weight loss of any 
duration. ǂ Three children were not treated with injectables: two had TB nephritis, and the third had disease 
caused by M. tuberculosis resistant to both capreomycin and kanamycin.*Comparison between pulmonary only TB 
and other forms. ¥ Grading of the adverse reactions adapted from Division of Microbiology and Infectious Diseases 
(DMID) paediatric toxicity tables, 2007. #Comparison of number of events. ˄ Comparison between favourable and 
unfavourable outcomes.  
 
 
 
 
